Skip to content

A Prospective Comparative Study of Contrast-Enhanced Ultrasound versus Conventional Ultrasound-Guided Biopsy for Ovarian Space-Occupying Lesions

A Prospective Comparative Study of Contrast-Enhanced Ultrasound versus Conventional Ultrasound-Guided Biopsy for Ovarian Space-Occupying Lesions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106034
Enrollment
Unknown
Registered
2025-07-16
Start date
2025-07-30
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian mass

Interventions

Gold Standard:Gold standard for surgical patients: histopathological diagnosis of postoperative resected specimens
Gold standard for non-surgical patients: > = 6 months of multimodal imaging follow-up (ultrasound/MRI once every 3 months) combined with comprehensive assessment of clinical outcomes (tumor markers, s
Malignancy: progression of lesions (volume increase >=10% or new metastases) with persistently elevated markers, or confirmation of malignancy by other routes (ascites cytology/metastases). Gold stand
Index test:Contrast-Enhanced Ultrasound-Guided Ovarian Biopsy Group (CEUS Group) Contrast agent: Sulfur Hexafluoride Microbubbles for Injection (SonoVue®, Bracco) Equipment: High-end ultrasound diagno

Sponsors

China-Japan Union Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Imaging examination shows that there is a clear space-occupying lesion of the ovary; 2. There is a safe puncture and material collection path under the real-time guidance of ultrasound.

Exclusion criteria

Exclusion criteria: 1. Hemoglobin < = 8.0 g/dL; 2. Patients with obvious bleeding tendency, such as platelets less than 50 × 10^9 / L, and/or patients with coagulation dysfunction that is difficult to correct, and a history of oral anticoagulants within the past week; 3. Patients with serious diseases of heart, lung, brain and other important organs at the same time, unable to tolerate surgery; 4. Patients with lesions that cannot be clearly displayed by ultrasound due to excessive obesity or abdominal distention; 5. Patients who are difficult to cooperate with or refuse to be punctured due to various other reasons.

Design outcomes

Primary

MeasureTime frame
Biopsy sampling success rate;Diagnostic accuracy;Negative predictive value;Sensitivity;

Secondary

MeasureTime frame
Average number of punctures;Incidence of intraoperative and postoperative 24-hour complications;

Countries

China

Contacts

Public ContactWang Hui

China-Japan Union Hospital of Jilin University

1192077396@qq.com+86 135 7870 8800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026